Increasing rates of infections caused by multidrug resistant Acinetobacter baumannii (MDRAB) and extensively drug resistant A. baumannii (XDRAB) have caused the need for searching alternative agents. The purposed of this project was to search plant-derived natural products that act as resistant modifying agents (RMAs) against A. baumannii. In this study, we further evaluated the activity of Holarrhena antidysenterica that has been previously proposed as RMA of novobiocin for a model strain, A. baumannii ATCC 19606 on clinically isolated non-MDRAB, MDRAB, and XDRAB. Effects of H. antidysenterica on outer membrane permeability and efflux pumps of the pathogen were conducted to preliminary elucidate mechanisms of this resistant modifier. Novobiocin was selected as a model antibiotic because it is well-established as an effective agent against Gram-positive pathogens. But, it possessed low level of antibacterial activity against Gram-negative pathogens due to an effective permeability barrier of these pathogens. H. antidysenterica ethanol extract possessed weak intrinsic antibacterial activity with minimum inhibitory concentration (MIC) more than 1000 g/mL. The extract, at concentrations of 250, 125, and 62.5 g/mL, remarkably enhanced the inhibitory effects of novobiocin (1/4 × MIC; 1-4 g/mL) against XDRAB isolates. Synergistic effects of novobiocin at 1/4 × MIC and 1/8 × MIC in combination with H. antidysenterica either at 31.2, 15.6, or 7.8 g/mL against clinical isolates non-MDRAB, MDRAB, and XDRAB were evidenced for 80% of the combinations (189 out of 234 combinations). Although, no enhancement of the accumulation of ethidium bromide was observed after treated with H. antidysenterica, this plant extract weakened the outer membrane of the pathogen as indicated by an increase in the N-phenyl-1-naphthylamine uptake. Our results suggested that H. antidysenterica which primarily interrupts membrane permeability should be further investigated as a promising resistant modifier for A. baumannii.
Introduction
An opportunistic bacterial pathogen, Acinetobacter baumannii or Iraqibacter has been recognized as a major cause of infections in combat troops who sustain injuries during the conflicts in Afghanistan and Iraq. During the last few decades, this pathogen was recognized as an important healthcare-associated pathogen and responsible for approximately 3-20% of Gram-negative infections (Vincent et al. 2009 ). In addition, a recent surveillance study in Thailand has documented that this pathogen is accountable for 30.4% of hospital-acquired pneumonia cases (Werarak et al. 2012) . A large number of reports describe outbreaks of A. baumannii infections typically occur in intensive care units such as bloodstream infections, urinary tract infections, secondary meningitis, wound and burn infections, and nosocomial pneumonia (Lee et al. 2007; Levin et al. 2003; Werarak et al. 2012) . Moreover, of particular concern is the increasing prevalence of multidrug resistant A. baumannii (MDRAB) and extensively drug resistant A. baumannii (XDRAB) which limits the effectiveness of prescribed antimicrobial agents and causes treatments for infections to fail (Manchanda et al. 2010) . Nosocomial bacteraemia due to MDRAB was associated with increased mortality rate as high as 30-50%, increased medical costs, and prolonged hospitalization (Lee et al. 2007) .
Initially, colistin has been recovered for treatments of infections caused by A. baumannii. Unfortunately, use of colistin is limited because of concerns on its toxicity (Falagas et al. 2006 ) and on resistance and heteroresistance in this pathogen (O'Hara et al. 2013) . Combination antibiotic therapy is a second strategy often employed in the treatment of MDRAB and XDRAB. For example, combination of colistin and rifampicin has demonstrated synergistic effects against A. baumannii both in vitro (Timurkaynak et al. 2006 ) and in clinical studies (Bassetti et al. 2008 ). However, the growth of A. baumannii isolates that had mutation in the rpoB target gene did not affect by this combination (Giannouli et al. 2012) .
With a reduction in the number of new agents that possess activity against Gram negative pathogen and increasing prevalence of MDR bacteria, there is an interest in the search for resistance modifying agents (RMAs) that restore or potentiate the activity of an antibiotic against a resistant strain and may also inhibit MDR mechanisms (Abreu et al. 2012; Gibbons 2005) . Previous experiments have demonstrated that molecules capable of blocking the action of efflux pumps such as reserpine (Stavri et al. 2007 ), carbonyl cyanide m-chlorophenylhydrazone (CCCP) (Chusri et al. 2009 ), and phenylalanine arginyl ␤-naphthylamide (PA␤N) have the potential to circumvent antimicrobial resistance. Unfortunately, their clinical application is difficult due to the toxicity, stability, and bioavailability of these molecules.
Holarrhena antidysenterica stem bark is commonly used in Thai traditional medicine and traditional Ayurvedic medicine for treatment of dysentery, particularly amoebic dysentery. Due to the presence of steroid alkaloids, this plant possesses antibacterial, anti-diarrhoeal, and astringent properties (Chakraborty and Brantner 1999) . We have previously shown that among 44 tested medicinal plants, H. antidysenterica in combination with novobiocin exhibited promising resistance modifying activity against A. baumannii ATCC 19606. As a part of our ongoing project to search for plant natural products which can modulate multidrug resistance in A. baumannii, the aims of this present study were (i) to evaluate the RMA activity of H. antidysenterica against clinical isolates of A. baumannii and (ii) to investigate the effects of H. antidysenterica on outer membrane permeability and efflux pumps of this pathogen.
Materials and methods

Preparation of H. antidysenterica extract
Fresh barks of H. antidysenterica were purchased from a medicinal herb retailer-Triburi Orsod in Songkhla, Thailand and authenticated by a taxonomist; Dr. Katesarin Maneenoon and voucher specimens were deposited at the Faculty of Traditional Thai Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand. Air dried and finely powdered material was macerated with 95% ethanol (500 mL) for 7 days at room temperature. After filtrations through a Whatman No. 1 paper, the filtrates were concentrated using a rotatory evaporator, and kept at 55 • C until they were completely dried. A stock solution (200 mg/mL) was prepared by dissolving the dried extract in dimethylsulfoxide (DMSO) (Merck, Germany).
Bacterial strains and culture condition
Clinically isolated A. baumannii were obtained from Songklanakarin Hospital from pus (n = 1), tissue (3), blood (n = 4), sputum (n = 13), body fluid (n = 10), and urine (n = 8) samples of infected patients. A standard laboratory strain of A. baumannii ATCC 19606 was employed as a quality control. Stock cultures were maintained at 4 • C on slopes of tryptic soy agar (TSA) (Difco Laboratories, Detroit, MI). Cultures for experiments were prepared by transferring a sample from these stock cultures and grown on TSA at 37 • C overnight. Well-isolated colonies from the plates were transferred into Mueller Hinton Broth (MHB) (Difco Laboratories, Detroit, MI) and incubated without agitation at 37 • C for 24 h. The suspensions were subsequently diluted with fresh MHB to achieve a bacterial culture concentration corresponding to 10 6 CFU/mL. Susceptibility test was performed by the disk diffusion method according to Clinical and Laboratory Standard Institute (CLSI) recommendations (CLSI 2011b).
Intrinsic antibacterial activity of novobiocin and H. antidysenterica
Minimum inhibitory concentrations (MICs) of the extract and novobiocin were tested by the CLSI broth microdilution method (CLSI 2011a). A 96-well sterile microtitre plate (Nunc, Denmark) was prepared by dispensing 100 L of the inoculated broth plus an aliquot of 100 L of two-fold serial dilutions of the extract (0.48-1000 g/mL) or the antibiotic (0.125-64 g/mL). An aliquot of 100 L of 1% DMSO was employed as a negative control. The plate was incubated for 24 h at 37 • C and the bacterial growth was measured by recording the absorbance at 620 nm, using a microplate reader (Sunrise, Tecan, Switzerland).
Resistant modifying ability of H. antidysenterica on A. baumannii clinical isolates
Resistance modifying ability of this extract was determined by growth inhibition assays as previously described (Phatthalung et al. 2012) . Briefly, the culture, containing 1 × 10 6 CFU/mL (100 L) was inoculated into a 96-well microtiter plate containing either (i) 50 L of the extract (31.2, 15.6, or 7.8 g/mL) or (ii) the antibiotic (50 L; at concentrations of 1/4 × MIC or 1/8 × MIC) or (iii) combinations of H. antidysenterica and novobiocin. The antibacterial activity was exhibited as the percentage of growth inhibition (GI) after incubation at 37 • C for 18 h and calculated from the following equation: GI (%) = [(OD control − OD test )/OD control ] × 100; Where OD control is optical density (OD) 620 nm of bacteria culture in MHB supplemented with 1% DMSO as a positive control and OD test is OD 620 nm of the bacterial culture in MHB supplemented with the tested agent. The OD test of respective blanks having only the extract was subtracted to give the final OD test .
Determination of resistance modifying mechanisms of H. antidysenterica
Uptake of a fluorescent probe N-phenyl-1-na phthylamine (NPN; Sigma-Aldrich, Steinheim, Germany) by bacterial membrane was utilized to determine permeability properties of outer membrane as described earlier (Alakomi et al. 2006; Ayres et al. 1999) . In this procedure, A. baumannii cells (1 × 10 6 CFU/mL) were pre-treated for 18 h at 37 • C with either a permeabilizer, ethylenediaminetetraacetic acid (EDTA; J.T. Baker, Phillipsburg, New Jersey) or H. antidysenterica extract at a final concentration of 40 M and 15.6 g/mL, respectively. Cells were subsequently harvested by centrifugation at 3000 rpm for 10 min at room temperature, washed twice, and re-suspended to an OD 595 nm of 1.0 in 50 mM PBS buffer (pH 7.4). Aliquots (100 L) of this cell suspension were added into wells of black microtiter plates with clear bottoms, which contained 50 L of NPN a final concentration of 40 M. The increase of fluorescence intensity was immediately monitored every 60 s for 10 min at room temperature (30 • C) using a Spectra-Max M5 microplate reader (Molecular Devices Corp., Sunnyvale, CA). The excitation and emission wavelengths were set at 350 and 420 nm, respectively.
Inhibition of bacterial efflux pump was assessed by an ethidium bromide (EtBr) whole cell accumulation assay (Chusri et al. 2009 ). Briefly, the suspension of A. baumannii cells that pre-treated with a positive control, carbonyl cyanide m-chlorophenlyhydrazone (CCCP; 20 M) or H. antidysenterica extract (15.6 g/mL) was prepared as described above. Aliquots (100 L) of this cell suspension were added into wells of black microtiter plates with clear bottoms. EtBr was then added into the tested plants to obtain a final concentration of 4 g/mL. The relative fluorescence intensity was immediately recorded every 60 s for 10 min using the fluorescence plate reader (excitation 518 nm; emission 605 nm).
The untreated bacterial cells were similarly processed and used as controls. Each assay was performed at least three times.
Results
Based on disk diffusion method, all A. baumannii isolates were resistant to ampicillin and the first generation cephalosporin, cephalothin. In addition, 64-97% of the analyzed isolates were not susceptible to second generation and third generation cephalosporins, carbapenems, fluoroquinolone, aminoglycoside, and extended beta-lactam in combination with beta-lactamase inhibitor. A total of 37 and 20 isolates were susceptible to colistin and sulperazone (cefoperazone in combination with sulbactam), respectively. With regard to the term 'extensive drug resistance (XDR)' defined by Manchanda et al. (2010) , 24 out of 39 tested isolates (61%) which were resistant to amikacin, ampicillin, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, cefuroxine, cephalothin, ciprofloxacin, ertapenem, gentamicin, meropenem, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole and susceptible to sulperazone and colistin were classified as XDRAB.
Resistant modifying agents or antibiotic adjuvants are classified as active molecules, preferably with non-antibiotic activities, which act synergistically in combination with antibiotics (Bernal et al. 2013) . Interestingly, this review revealed that the anti-Escherichia coli activity of novobiocin as well as other classified Gram-positive antibiotics was enhanced by an antibiotic adjuvant. In this study we used A. baumannii, which is one of the most troublesome Gramnegative bacteria as a model pathogen. Therefore, the intrinsic antibacterial activities of this GyrA inhibitor and a promising RMA, H. antidysenterica ethanol extract against the clinical A. baumannii isolates were firstly tested. It was found that this extract possessed weak antibacterial activity (MIC > 1000 g/mL) whereas this antibiotic showed MICs of 4, 8, and 16 g/mL against 7, 19, and 14 isolates, respectively (Table 1 and Fig. 1 ).
Inhibitory activity of H. antidysenterica extract as a resistance modifier for novobiocin against XDRAB was assayed, at concentrations of 250, 125, and 62.5 g/mL which had low intrinsic effect on the growth of these isolates (Fig. 2) . Concentrations of novobiocin were chosen to be 1/4 and 1/8 of its MIC to guarantee that the effect produced is due to the combination and not to the effect of the antibiotic alone. The extract of H. antidysenterica remarkably enhanced the inhibitory effects of novobiocin against XDRAB. Combinations of the extract with 1/4MIC of novobiocin showed higher antibacterial activity against the tested isolates, while combinations of the extract with 1/8MIC of novobiocin possessed very lower activity. The efficacy of the combinations in enhancing anti-XDRAB activity was generally greater on the isolates which had MIC value of novobiocin at 16 g/mL. The combinations of novobiocin with H. antidysenterica either at 250 g/mL or 125 g/mL reduced more than 90% of the growth of these isolates (Fig. 2 C) . Notable growth inhibition induced by these combinations was observed in 3 out of 6 and 9 out of 10 of XDR AB isolates which MIC values of novobiocin at 4 and 8 g/mL, respectively ( Fig. 2A and B ).
Subsequently, we tested a possible synergistic effect of novobiocin at 1/4MIC and 1/8MIC in combination with H. antidysenterica either at 31.2, 15.6, or 17.8 g/mL on non-MDRAB, MDRAB, and XDRAB isolates. Based on criteria that have been proposed by Wagner and Ulrich-Merzenich (2009), synergistic activities were found in 80% of the combinations (189 out of 234 combinations) against A. baumannii isolates (Table 2) . Synergistic effects were observed in the combinations of novobiocin (at 1/4MIC; MIC = 16 g/mL) and H. antidysenterica (at 31.2, 15.6, or 17.8 g/mL) against all tested isolates of A. baumannii. This medicinal plant species which possessed non-intrinsic antibacterial activity could significantly enhance activity of novobiocin against 65-86% of A. baumannii isolates that possessed MIC of novobiocin at 4 and 8 g/mL.
The effects of H. antidysenterica on the membrane permeability and active efflux pumps of A. baumannii were conducted. In the presence of the efflux pump inhibitor, CCCP, the accumulation of EtBr was dramatically increased, while no enhancement of the accumulation was observed after treated with H. antidysenterica (Fig. 3B) . Results of NPN uptake experiments with the permeabilizer, EDTA (40 M) and H. antidysenterica (16 g/mL) is presented in Fig. 3A . As indicated by an increase in the NPN uptake, the activity of the plant extract was comparable with EDTA that weakened the outer membrane of the reference strain, A. baumannii ATCC 19606.
Discussion
Numerous outbreaks of both MDRAB and XDRAB have necessitated the search for alternative agents. We have previously shown that among 55 ethanol extracts obtained from 44 different medicinal plants, H. antidysenterica significantly improved the activity of novobiocin against a reference strain, A. baumannii ATCC 19606 (Phatthalung et al. 2012) . In this study, we further demonstrated that H. antidysenterica could enhance the activity of novobiocin against XDRAB, MDRAB, and non-MDRAB clinical isolates. Particularly, ethanol extract of this plant (at 62.5-250 g/mL) with low intrinsic antibacterial activity, in combination with 1/4MIC of novobiocin, resulted in a marked decrease in the growth of XDRAB isolates. Interested in plant-derived compounds as natural RMAs was firstly reported in 2000 by Stermitz and his team (Stermitz et al. 2000a,b) . The studies have shown that 5 -methoxyhydnocarpin produced by Berberis fremontii significantly enhanced the activity of plant-isolated antibacterial agents, antibiotics, disinfectants, and dyes against Staphylococcus aureus. A synergistic mechanism of this compound was classified as NorA efflux pump inhibitor. Since that time, several plant-derived compounds such as harmaline, piperine (Mohtar et al. 2009 ), epigallocatechin gallate (Gibbons et al. 2004) , tellimagrandin I, and rugosin B (Shiota et al. 2000) have been proposed as effective RMAs for Gram-positive pathogens. However, the scientific data of RMAs conducted in Gram-negative pathogens, particularly A. baumannii is limited.
A steroidal alkaloid, conessine is well-established as an active principle of H. antidysenterica bark. Although the antibiotic resistant modifying ability of active principles of H. antidysenterica has never been reported, four plant-derived alkaloids consisting of reserpine, quinine, harmaline, and piperine have been well-clarified as efflux pump inhibitors (EPIs) for Streptococcus pneumoniae (Garvey and Piddock 2008) , S. epidermidis (Sierra et al. 2009 ), and methicillin-resistant S. aureus (Mohtar et al. 2009 ). A recent study has also proposed that a well-characterized efflux pump inhibitor, 1-(1-naphtylmethyl)-piperazine was able to restore ciprofloxacin susceptibility in clinical isolates of A. baumannii (Coban et al. 2011) .
Low permeability of outer membrane and constitutive expression of efflux pumps that similar to other Gram-negative pathogens are responsible to intrinsic resistant mechanisms of novobiocin in A. baumannii (Damier-Piolle et al. 2008; Savage 2001) . Exposure of bacterial cells to the outer membrane-permeabilizing The minimum inhibitory concentrations of novobiocin against clinical isolates of A. baumannii were 4, 8, and 16 g/mL as indicated by the superscript letters 'a' 'b' and 'c' respectively. Bold text represent the bacterial growth inhibition by the combinations greater than 50%.
such as EDTA increased their sensitivity to hydrophobic antibiotics and detergents. As a consequence, the cells also incorporate increased amounts of the hydrophobic probe NPN. Because of its characteristic strong fluoresces in phospholipid environment, NPN uptake is widely used in quantifying the outer membrane damage. The results obtained from this study revealed that the resistant modifying mechanism of H. antidysenterica was similar to that of the permeabilizer EDTA which increased the bacterial uptake of NPN. On the other hand the ethanol extract of this plant did not affect the accumulation of a substrate of efflux pump, EtBr. It has been reported that activity of novobiocin against A. baumannii as well as other Gramnegative bacteria, such as Pseudomonas aeruginosa (Ayres et al. 1999) , Stenotrophomonas morelense (Alakomi et al. 2006) , and Salmonella enterica Typhimurium enhanced by compounds that efficiently destabilize outer membrane permeability such as EDTA, polyethyleneimine, and berry-derived phenolic compounds (Chusri et al. 2009 On the other hand, ellagic acid that exhibited a synergistic effect with novobiocin and increased the accumulation of pyronin Y did not affect the bacterial uptake of NPN or the accumulation of EtBr (Chusri et al. 2009 ).
The results presented in this study showed that H. antidysenterica remarkably improves the activity of a model antibiotic, novobiocin against clinical isolates of A. baumannii, particularly XDRAB and causes an increasing of NPN uptake of the treated cells. The findings emphasize the conclusion that H. antidysenterica which acts primarily as a permeabilizer and active principles that responsible for this activity should be further investigated as a promising resistant modifier for A. baumannii. 
